Lin BioScience, Inc. (TPEX:6696)

Lin BioScience Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Apr 8, 2025	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	7,199	8,946	12,583	12,832	6,987	1,815
Market Cap Growth	-21.39%	-28.90%	-1.94%	83.66%	284.89%	-17.98%
Enterprise Value	4,884	7,788	11,314	11,817	6,797	1,639
Last Close Price	91.50	113.24	170.33	180.59	99.04	29.11
PB Ratio	2.83	2.61	7.25	28.33	7.68	12.72
P/TBV Ratio	2.97	4.41	11.18	28.87	8.60	50.80
Debt / Equity Ratio	0.01	0.01	0.03	0.01	0.01	0.48
Quick Ratio	31.70	23.70	20.60	1.72	3.56	1.16
Current Ratio	32.96	24.69	20.94	1.74	3.62	1.29
Return on Equity (ROE)	-37.51%	-41.08%	-41.98%	-70.57%	-28.85%	-90.44%
Return on Assets (ROA)	-23.80%	-25.16%	-20.05%	-19.74%	-16.78%	-46.23%
Return on Capital (ROIC)	-24.71%	-26.09%	-24.87%	-30.86%	-21.87%	-50.63%
Earnings Yield	-10.16%	-7.68%	-2.49%	-3.39%	-2.17%	-12.96%
FCF Yield	-16.52%	-11.34%	-3.05%	-2.27%	-2.59%	-11.70%
Buyback Yield / Dilution	-6.63%	-3.14%	-4.27%	-10.73%	-4.42%	-0.03%

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.